Trump announces trade deal with EU following months of negotiations
Karen Akinsanya, President of R&D, Therapeutics at Schrodinger, Inc. (NASDAQ:SDGR), recently sold shares worth $419,570, according to a recent SEC filing. The transactions took place on April 14, 2025, with shares sold at prices ranging from $25.00 to $25.1123. Akinsanya’s sales were executed under a Rule 10b5-1 trading plan, which was adopted in December 2024.
Akinsanya also exercised stock options, acquiring 16,723 shares at prices between $2.92 and $3.22, totaling $52,844. Following these transactions, Akinsanya holds 15,625 shares, which include unvested restricted stock units (RSUs).
These transactions reflect Akinsanya’s strategic management of her equity holdings in Schrodinger as the company continues its endeavors in the pharmaceutical preparations industry.
In other recent news, Schrödinger, Inc. reported its fourth-quarter 2024 earnings, exceeding analysts’ expectations with an earnings per share (EPS) of -$0.24 compared to the forecasted -$0.33. The company’s revenue also surpassed projections, reaching $88.3 million against the anticipated $82.8 million. Schrödinger’s total revenue for the year was $288 million, a significant increase from $217 million in 2023, with software revenue contributing $180 million, marking a 13.3% growth year-over-year. In another development, Schrödinger has settled a lawsuit regarding its non-employee director compensation practices, agreeing to pay $390,000 in attorneys’ fees and implement corporate governance reforms. The company also announced the appointment of Bridget van Kralingen to its Board of Directors, bringing her extensive experience from IBM (NYSE:IBM) and other roles. Additionally, Schrödinger expressed support for the FDA’s move away from animal testing, aligning with its initiatives to advance drug discovery through computational methods. These recent developments highlight Schrödinger’s ongoing efforts to innovate and strengthen its market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.